Dr. Saloum Cisse, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 119 S Oak, Suite 2, Raymond, MS 39154 Phone: 601-526-0790 Fax: 601-526-0795 |
News Archive
Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.
SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.
Whitehead Institute researchers have pinpointed a cellular pathway that determines whether cancerous tumors respond to dietary restriction during their development.
QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.
Healthcare facilities continue to battle drug-resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) that loiter on surfaces even after patient rooms have been cleaned and can cause new, sometimes-deadly infections.
› Verified 3 days ago